Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Julie Laplante

Nurse Practitioner, Family Concord, NH Nurse Practitioner

NPI 1588016430 CMS profile 10775774

81 Hall St, Concord, NH 03301

Open in the dashboard

General payments

$2,269

101 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Laplante of Concord, NH is reported in the CMS Open Payments database as having received $2,269 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,125 52
2024 General $938 39
2023 General $206 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Laplante
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Julie Laplante were reported at $1,125. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Julie Laplante Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $206 $154 $49–$476 $160
2024 $938 $165 $51–$504 $164
2025 $1,125 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $687 28 payments
  2. Lilly USA, LLC $305 16 payments
  3. Pfizer Inc. $246 14 payments
  4. Novo Nordisk Inc $198 10 payments
  5. Merck Sharp & Dohme Corporation $162 6 payments
  6. Inspire Medical Systems, Inc. $149 3 payments
  7. AstraZeneca Pharmaceuticals LP $99 4 payments
  8. GlaxoSmithKline, LLC. $86 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $71 3 payments
  10. ITI, Inc. $58 2 payments
  11. Other $209 10 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,269 101 payments
Products named General payments · program years 2023–2025
  1. UBRELVY $605 24 payments
  2. MOUNJARO $247 13 payments
  3. NURTEC ODT $183 10 payments
  4. ZEPBOUND $166 9 payments
  5. GARDASIL 9 $162 6 payments
  6. INSPIRE $149 3 payments
  7. Ozempic $132 7 payments
  8. VAXELIS $129 5 payments
  9. QULIPTA $106 5 payments
  10. PAXLOVID $89 5 payments
  11. Other $1,476 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

593

Median for Nurse Practitioner: 389

Drug cost

$26,512

Median for Nurse Practitioner: $21,885

Branded share of claims

17.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 14 $22,457
Synthroid Levothyroxine Sodium Brand 18 $1,105
Sertraline Hcl Generic 33 $379
Levothyroxine Sodium Generic 48 $358
Albuterol Sulfate Hfa Albuterol Sulfate Brand 26 $327
Metoprolol Tartrate Generic 19 $219
Losartan Potassium Generic 37 $216
Dicyclomine Hcl Generic 11 $161
Rosuvastatin Calcium Generic 11 $136
Omeprazole Generic 31 $131

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $136
$136 — —
MOUNJARO
  • Lilly USA, LLC $74
$74 14 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $69
$69 — —
ZEPBOUND
  • Lilly USA, LLC $27
$27 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record